Aerie pharmaceuticals reports third quarter 2020 financial results and provides business update

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the third quarter ended september 30, 2020 and provided a general business update. “our third quarter results demonstrated over 12 percent sequential growth in o
AERI Ratings Summary
AERI Quant Ranking